Slide 1: Investor Presentation Q3 and 9M2025
INVESTOR PRESENTATION IMEXPHARM CORPORATION Q3 and 9M2025
Slide 2: Strong 9M performance and steady progress toward year-end targets
Strong 9M performance and steady progress toward year-end targets Year-end target completion Gross revenue ▲ 21% yoy 71% VND 2,118 billion New SKUs 20 Net revenue ▲ 16% yoy 68% VND 1,800 billion EBITDA ▲ 18% yoy 63% On-going VND 402 billion projects 144 PBT ▲ 23% yoy 63% VND 311 billion 2
Slide 3: Resilient Q3 amid regulatory and market volatility, ending with an outstanding September
Resilient Q3 amid regulatory and market volatility, ending with an outstanding September Net revenue 3Q September Net revenue VND 574 bn ETC VND 218 bn OTC ▲ 5% YoY ▲ 4% YoY ▲ 25% MoM ▲ 16% YoY ▼ 6.5% YoY EBITDA 3Q September EBITDA VND 133 bn VND 58 bn Net 14,3% 13,4% ▲ 12% YoY 12,5% ▲ 22% YoY ▲ 48%
Slide 4: Robust profitability fueled by sustainable sales growth & continued COGS optimization
Robust profitability fueled by sustainable sales growth & continued COGS optimization VND bn 2118,40 1800,30 (318,10) 715,10 (1085,20) 92,0 401,50 311,0 (392,30) (11,80) Gross revenue Sales deduction Net revenue COGS Gross Profit SG&A expense Others PBT Int,Dep,Amor EBITDA YoY 21% 65% 16% 13% 21% 19
Slide 5: OTC recorded an impressive turn-around while ETC continued its momentum
OTC recorded an impressive turn-around while ETC continued its momentum Revenue (VND bn) Gross revenue before accrued promotional cost 21% yoy Gross revenue +21% 54% 43% 3% ETC OTC Others ETC Channel 21% yoy 2.118 1.745 • Entered a more sustainably growing phase, with 9M25 revenue up 21% based on a
Slide 6: Continued improvement in cost efficiency alongside revenue expansion
Continued improvement in cost efficiency alongside revenue expansion COGS (VND bn) • Cost of goods sold increased by 13% yoy, lower than the +13% net revenue growth rate of 16%, thanks to well managed stock level, campaign-based production and optimized 963 1.085 maintenance fee • API cost per unit
Slide 7: Production at EU-GMP factories continued to grow to meet increasing demand
Production at EU-GMP factories continued to grow to meet increasing demand 4% 8% 832 9M24 776 38% Revenue by Factory 691 686 9M25 IMP1 IMP2 (VND Bn) 36% 9M25 305 IMP3 IMP4 234 179 Others 114 73 82 IMP1 IMP2 IMP3 IMP4 Others 14% Production volume Production volume Factory Production by Factory 3Q25 v
Slide 8: More penetration in Tier 1 and Tier 2 tenders
More penetration in Tier 1 and Tier 2 tenders Market tender value IMP tender value (VND Tn) (VND Bn) 8,9 8,7 8,0 7,6 6,8 6,8 1.0% 22.9% %MS 14.6% 0.4% 0.4% 1Q25 0.5% 5.6 5.1 5.5 4,7 2Q25 840,2 4,0 3.9 3,7 3.5 3Q25 686,2 3.4 619,1 1Q25 2024 2.2 2.4 2Q25 1.6 3Q25 98,2 68,2 43,0 34,9 25,0 31,3 Tier 1 T
Slide 9: Balanced product mix as both antibiotics and non-antibiotics are growing strongly
Balanced product mix as both antibiotics and non-antibiotics are growing strongly 9.1% 76% 24% 4.4% 3.5% Non-antibiotics key products 2.9% 0.9% ❖ Cough medicine: 38% yoy 1.3% 1.3% 0.9% ❖ Digestive aid: 22% yoy Antibiotics Cough medicine ❖ Anti-inflammatory: 27% yoy Digestive aid Analgesic and antipy
Slide 10: IMP: Outperforming pharma industry and market
IMP: Outperforming pharma industry and market % 160 120 Weighted avg. share price of IMP stock price top 6 pharma companies by revenue 80 40 VNIndex 0 -40 Stock price (VND) 52,900 IMP Market cap (VND) Average daily trading volume in 9M25 (shares) 8,147 Bn 188,739 Up 14% ytd x3 vs. 9M24 average (HOSE
Slide 11: 3Q2025 Market update
3Q2025 Market update Resolution No. 72-NQ/TW (Sept) outlines a roadmap for universal preventive healthcare - from 2026, all citizens will receive one free annual health check-up, and by 2030, basic hospital fees will be waived under health insurance, driving increased demand for diagnostics and prim
Slide 12: Thank You
Thank You For further discussion, please contact our IR team ir@imexpharm.com 12